No Rise in Cancer Risk for RA Patients on Actemra
(MedPage Today) -- Similar to malignancy risk with TNF inhibitors and abatacept (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 14, 2019 Category: Primary Care Source Type: news

Abatecept Retention Longest When Used First-Line (CME/CE)
(MedPage Today) -- Also, starting abatacept sooner may improve efficacy in rheumatoid arthritis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 7, 2019 Category: Primary Care Source Type: news

Abatacept Retention Higher Without Prior Biologics
(MedPage Today) -- Earlier use in rheumatoid arthritis may improve efficacy (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 25, 2019 Category: Primary Care Source Type: news

Abatacept and Joint Surgery: The Best Time to Stop? (CME/CE)
(MedPage Today) -- Pre-surgical biologic hold for one dosing interval not tied to lower risk of hospitalized infection, other outcomes (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 21, 2019 Category: Primary Care Source Type: news

Stopping Biologics Before Joint Surgery: Is Earlier Better?
(MedPage Today) -- For abatacept, one dosing interval sufficed in RA patients (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 12, 2019 Category: Primary Care Source Type: news

Abatacept Versus TNF Inhibitors in RA: What Are the Risks of Infections? (CME/CE)
(MedPage Today) -- Reduced hospitalized infection risk in abatacept versus TNFi initiators, study found. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 2, 2019 Category: Primary Care Source Type: news

Infection Risk Lower With Orencia vs Anti-TNF
(MedPage Today) -- Increased risk for hospitalized infection with TNF inhibitors was driven largely by infliximab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 26, 2018 Category: Primary Care Source Type: news

Two-Drug Regimen Fails to Stem Psoriasis Relapse
(MedPage Today) -- Study looks at costimulatory blockade with abatacept after stopping ustekinumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 18, 2018 Category: Primary Care Source Type: news

Abatacept Misses the Mark in Lupus Nephritis
(MedPage Today) -- But further analyses planned because of " provocative " findings (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - June 19, 2018 Category: Rheumatology Source Type: news

Abatacept a Winner in JIA
(MedPage Today) -- Subcutaneous treatment effective in arthritic kids as young as 2 (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - February 28, 2018 Category: Pediatrics Source Type: news

Abatacept Shows Promise for RA-ILD (CME/CE)
(MedPage Today) -- Most patients'symptoms and pulmonary function remained stable (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 1, 2018 Category: Primary Care Source Type: news

Immunotherapy drug nearly eliminates severe acute graft-versus-host disease
(Seattle Children's) Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 9, 2017 Category: Cancer & Oncology Source Type: news

FDA approves Bristol-Myers Squibb ’s Orencia for active psoriatic arthritis
The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb ’s Orencia for the treatment of adult patients with active psoriatic arthritis (PsA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 10, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb ’s Orencia (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis in Adults
PRINCETON, N.J.--(BUSINESS WIRE) July 6, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA) has approved Orencia for the treatment of adults with active Psoriatic Arthritis (PsA)1, a chronic2,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 6, 2017 Category: Drugs & Pharmacology Source Type: news

Bristol-Myers Squibb launches prefilled syringe option for arthritis drug
Bristol-Myers Squibb (NYSE:BMY) launched a subcutaneous administration option for Orencia, a biologic indicated for severely active polyarticular juvenile idiopathic arthritis in patients who are at least 2 years old. The prefilled syringe enables physicians, caregivers and patients to administer Orencia at home. Get the full story at our sister site, Drug Delivery Business News. The post Bristol-Myers Squibb launches prefilled syringe option for arthritis drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 8, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pediatrics Pharmaceuticals Wall Street Beat Bristol-Myers Squibb Co. Source Type: news

Abatacept Helps Joints in Psoriatic Arthritis (CME/CE)
(MedPage Today) -- Benefits were less for skin manifestations (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 7, 2017 Category: Dermatology Source Type: news

Orencia (Abatacept) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 17, 2017 Category: Drugs & Pharmacology Source Type: news

Common Drugs Boost Diabetes Risk in RA Patients (CME/CE)
(MedPage Today) -- Hydrochloroquine, abatacept associated with reduced risk (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 25, 2016 Category: Cardiology Source Type: news

US as a Marker of Early Response to Abatacept in RA US as a Marker of Early Response to Abatacept in RA
Ultrasound can play an important role in assessing the early efficacy of abatacept among biologic-naive rheumatoid arthritis patients.Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

EU Clears Abatacept (Orencia) for MTX-Naive Patients With RA EU Clears Abatacept (Orencia) for MTX-Naive Patients With RA
Abatacept is indicated in combination with methotrexate for adults with highly active or progressive RA who have not previously been treated with methotrexate.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 6, 2016 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Abatacept fails to provide benefit in relapsing-remitting MS
Results from the double-blind, randomized, placebo-controlled phase II ACCLAIM study indicate that abatacept has no effect on reducing the number of new gadolinium-enhancing lesions on MRI in... (Source: Clinical Neurology News)
Source: Clinical Neurology News - August 2, 2016 Category: Neurology Source Type: news

CHMP Backs Abatacept (Orencia) for MTX-Naive Patients With RA CHMP Backs Abatacept (Orencia) for MTX-Naive Patients With RA
The EMA's Committee for Medicinal Products for Human Use recommended marketing authorization for abatacept in combination with methotrexate for methotrexate-naive adults with rheumatoid arthritis. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2016 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

Bristol-Myers Squibb launches Orencia ClickJect drug-device combo for rheumatoid arthritis
Bristol-Myers Squibb said today it launched the Orencia ClickJect autoinjector designed for the self-administration of Orencia to treat moderate to severe rheumatoid arthritis. The Orencia ClickJect is designed to deliver 125 mg of subcutaneous Orencia through a push button operation with injection confirmation to reduce the possibility of user errors, the company said. “Today’s launch of the Orencia ClickJect is an example of our continued commitment to offering patients with moderate to severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector....
Source: Mass Device - July 21, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Bristol-Myers Squibb Co. Source Type: news

Abatacept Monotherapy vs Abatacept Plus DMARDs in RAAbatacept Monotherapy vs Abatacept Plus DMARDs in RA
What benefits do the addition of DMARDs to abatacept therapy offer patients with rheumatoid arthritis? Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2016 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Hydroxychloroquine, abatacept linked with reduced type 2 diabetes
LONDON – U.S. rheumatoid arthritis patients had a significantly reduced incidence of type 2 diabetes when on treatment with either hydroxychloroquine or abatacept in an analysis of more than 13,000... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 10, 2016 Category: Endocrinology Source Type: news

IV to SC Switch OK for Orencia in RA (CME/CE)
(MedPage Today) -- Going on vacation and don't want to bring meds along? (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 23, 2016 Category: Geriatrics Source Type: news

Monotherapy an Option in RA With Orencia (CME/CE)
(MedPage Today) -- Suitable for patients who can't tolerate methotrexate (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 14, 2016 Category: Geriatrics Source Type: news

Orencia: Try Again in Lupus? (CME/CE)
(MedPage Today) -- Benefits seen for articular symptoms (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 31, 2016 Category: Primary Care Source Type: news

Sustaining Remission After RA Therapy Ends Sustaining Remission After RA Therapy Ends
Dr Deane discusses results from a randomized trial evaluating maintenance of remission after rapid withdrawal of abatacept and methotrexate--alone or in combination. Medscape Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 30, 2016 Category: Consumer Health News Tags: Rheumatology Viewpoint Source Type: news

Antibodies Predict RA Response to Orencia (CME/CE)
(MedPage Today) -- Patients seropositive for rheumatoid factor or ACPA less likely to stop abatacept (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 8, 2016 Category: Geriatrics Source Type: news

Review Shows Varying Safety of Rheum Biologics (CME/CE)
(MedPage Today) -- Results generally favor Orencia and others over Remicade in autoimmune disorders (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - December 23, 2015 Category: Geriatrics Source Type: news

Orencia Does Not Ruin Pneumonia Vax Efficacy (CME/CE)
(MedPage Today) -- Abatacept suppresses immune response a bit, but vaccine should still work (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - December 18, 2015 Category: Rheumatology Source Type: news

Orencia Safe in RA, Even With HBV (CME/CE)
(MedPage Today) -- An Italian study found no cases of viral reactivation over 2 years (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - November 20, 2015 Category: Geriatrics Source Type: news

Antibodies and RA Treatment: Is There a Link? (CME/CE)
(MedPage Today) -- Anti-citrullinated protein antibodies levels predicted response with Orencia, but not Humira (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - September 15, 2015 Category: Geriatrics Source Type: news

Orencia, Actemra Comparable for RA Treatment (CME/CE)
(MedPage Today) -- Similar efficacy, but baseline predictors of response differed (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 11, 2015 Category: Geriatrics Source Type: news

Abatacept Might Be First-Ever Treatment for Rare Immune DeficiencyAbatacept Might Be First-Ever Treatment for Rare Immune Deficiency
Some devastating aspects of common variable immune deficiency are a result of a defect in trafficking of the immune down-regulator CTLA4, which can be overcome by treatment with abatacept. Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 4, 2015 Category: Allergy & Immunology Tags: Family Medicine/Primary Care News Source Type: news

Abatacept Safety, Efficacy Maintained in JIA (CME/CE)
(MedPage Today) -- Phase III study reports reduction of adverse events with long-term use (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 29, 2015 Category: Geriatrics Source Type: news

Rituxan Cost-Effective Choice After TFN Inhibitors Fail (CME/CE)
(MedPage Today) -- For RA patients, rituximab is equivalent to IV abatacept in safety and efficacy (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 4, 2015 Category: Primary Care Source Type: news

RA: Infection Risk Lower With Enbrel or Orencia (CME/CE)
(MedPage Today) -- Studies are needed to balance harms and benefits of different biologics in individual patients. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - May 26, 2015 Category: Consumer Health News Source Type: news

abatacept, Orencia
Title: abatacept, OrenciaCategory: MedicationsCreated: 2/8/2006 12:00:00 AMLast Editorial Review: 4/7/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - April 7, 2015 Category: Drugs & Pharmacology Source Type: news

RA Remission May Hold Steady After Stopping Abatacept (CME/CE)
(MedPage Today) -- Remission predicted by HAQ-DI score or C-reactive protein at baseline. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - April 3, 2015 Category: Geriatrics Source Type: news

Evaluating Drug-free Remission With Abatacept in Early RAEvaluating Drug-free Remission With Abatacept in Early RA
Does the addition of abatacept to MTX therapy help achieve drug-free remission in early rheumatoid arthritis? Annals of the Rheumatic Diseases (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 17, 2015 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Lower Maintenance Abatacept Dose Maintains RA Remissions (CME/CE)
(MedPage Today) -- Even half doses help RA patients maintain reduced disease activity (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - January 16, 2015 Category: Geriatrics Source Type: news

Psoriatic Arthritis: Biomarkers May Predict Drug Response Psoriatic Arthritis: Biomarkers May Predict Drug Response
A 1-step test of 57 synovial tissue proteins may predict which patients with psoriatic arthritis would benefit from adalimumab or abatacept. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Durable Drug-Free Remission Possible for RADurable Drug-Free Remission Possible for RA
Some adults with active rheumatoid arthritis (RA) achieved drug-free remission at 12 months after first-line treatment with abatacept, and a proportion remained drug-free up to 18 months. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Orencia Combo Tops in Early, Severe RA
PARIS (MedPage Today) -- In a study of patients with poor-prognosis early rheumatoid arthritis, more patients treated with abatacept (Orencia) plus methotrexate were in remission at 1 year than were those on methotrexate alone, a researcher reported here. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 12, 2014 Category: Geriatrics Source Type: news

Effectiveness of Abatacept for RA in Europe and CanadaEffectiveness of Abatacept for RA in Europe and Canada
IV abatacept may be a safe and effective therapeutic option for patients with moderate-to-severe rheumatoid arthritis. BMC Musculoskeletal Disorders (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2014 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Orencia Aids Beta Cell Function (CME/CE)
(MedPage Today) -- Immune modulation with abatacept (Orencia) helped slow the decline of beta cell function in patients with recent-onset type 1 diabetes even after the treatment stopped, researchers reported. (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - December 4, 2013 Category: Endocrinology Source Type: news

Orencia Slows Proteinuria in Renal Disease (CME/CE)
ATLANTA (MedPage Today) -- Proteinuria resolved partly or completely in a small group of patients with focal segmental glomerulosclerosis treated with abatacept, according to a study reported here. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - November 9, 2013 Category: Primary Care Source Type: news

Kidney Week 2013: New clinical trials reveal insights on treating patients with kidney disease
(American Society of Nephrology) An investigational drug called ZS-9 demonstrated promising Phase 2 clinical trial results for treating abnormally high potassium levels in patients with chronic kidney disease.The immune drug abatacept did not provide benefits above standard treatment for patients with kidney inflammation caused by lupus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 9, 2013 Category: Global & Universal Source Type: news